Navigation Links
UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease
Date:10/18/2010

ATLANTA, Oct. 18 /PRNewswire/ -- Findings from the PRECiSE 3 (P3) open label extension study for Cimzia® (certolizumab pegol; CZP), demonstrating the longest continuously running maintenance trial for an anti-TNF in Crohn's disease, will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology (ACG), taking place in San Antonio from October 15 – 20.  Additionally, long-term efficacy data from the PRECiSE 4 (P4) clinical trial also will be presented at the meeting.

Results of the P3 open-label extension study showed that continuous therapy with Cimzia provided long-term remission for more than 4.5 years in patients who initially responded to Cimzia in the six-month PRECiSE 2 study (P2).  In the PRECISE 2 double blind, placebo controlled clinical trial, 48% of patients achieved remission at six months.  Sustained long-term remission was observed among patients who had previous anti-TNF exposure (77% remission), as well as anti-TNF naive patients (73% remission).  

Similarly, results of the P4 open-label extension study showed long-term remission rates among patients treated with Cimzia (naive – 63%; non-naive – 50%).  For some patients, disease remission was achieved in as early as 4 weeks (38% of patient population).  Additionally, the data demonstrates that patients who are losing response to Cimzia or experience an interruption in therapy can be recaptured with one additional dose of Cimzia.  The data suggests re-induction therapy may have long-term benefits in helping patients who experienced drug interruption or loss of initial response achieve response and maintain remission.

"Collectively, these Cimzia data findings are important for patients living with moderate to severe Crohn's disease and the gastroenterologists treating them, as long-term remission is the ultimate goal of treatment," said Cem Kayhan, MD, Medical Director at UCB.  "It
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 Inovio Pharmaceuticals, Inc. ... a conference call to report its second quarter 2014 ... AM ET. CEO Dr. J. Joseph Kim ... quarter earnings, provide a corporate update, and participate in ... clinical development plans for VGX-3100, Inovio,s immune therapy targeting ...
(Date:8/1/2014)... -- DeepResearchReports.com adds "2014 Deep Research Report on ... Deep Research Report on Global and China Tricalcium ... Photo - http://photos.prnewswire.com/prnh/20140731/132164 ... Global and China Potassium Nitrate  Industry" is a ... China and Global Potassium Nitrate  market. ...
(Date:7/31/2014)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) ... Chief Business Officer and Executive Vice President. Mr. Singh died ... "Sorrento is deeply saddened and shocked by the ... go to Amar,s family and friends," said Henry Ji ... Mr. Singh joined Sorrento in January 2014 from Synta ...
Breaking Medicine Technology:Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... Society for Biomolecular Sciences Conference, THE WOODLANDS, ... Incorporated announced that data was presented,today highlighting ... Genentech, Inc. at the Society for Biomolecular,Sciences ... These target discoveries were made in a ...
... BASKING RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ ... company focused on acquiring, developing and,commercializing targeted ... of VQD- 002, a direct inhibitor of ... hematologic tumors.,Pre-clinical data was presented in a ...
Cached Medicine Technology:Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 2Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 3Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 4Lexicon-Genentech Collaboration Yields Potential Therapeutic,Targets 5VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:8/1/2014)... August 01, 2014 The evolving ... independent community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and ... with practices and resources to enhance patient care ... focused on critical issues to give independent pharmacists ... grow. , ThoughtSpot show attendance experienced a ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, medical ... boosting healthcare market growth, although a reduction in ... generic consumption is a major challenge. , Turkey’s ... having grown at a Compound Annual Growth Rate ... the Health Transformation Program (Saglikta Donus, um Programi, ...
(Date:8/1/2014)... (HealthDay News) -- Patients with the progressive, deadly respiratory ... a new weapon to battle the disease, the U.S. ... agency approved a new treatment, an inhaled spray called ... of Americans. COPD, which is often linked to smoking, ... emphysema. Patients with COPD may experience a ...
(Date:8/1/2014)... August 01, 2014 For years, proponents ... A recent study conducted by the Ohio ... too far behind in terms of their health and ... know what’s best for their baby. So does this ... Dr. Steven Shapiro , chair of Pediatrics at ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Oxford ... company develops biomarkers. Its products include CytoSure heamatological ... +SNP Array, CytoSure ISCA UPD array, CytoSure ISCA ... array. OGT offers services, such as targeted sequencing ... service, miRNA analysis, gene expression analysis, cytosure services ...
Breaking Medicine News(10 mins):Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3
... ... ... ... ...
... The U.S. ,race gap, in the commission of violent crime ... arrest rates for African Americans out-distancing those for whites concludes ... University and the University of Oregon. While the gap ... grew again in the ,80s with the advent of crack cocaine. ...
... ... of the New England ADHD Treatment Center are excited to announce a new five week ... ... and Dr. Jeffrey Speller of the New England ADHD Treatment Center are excited to ...
... ... “ADDY” Awards at the 2010 ADDY Awards Ceremony presented in Akron, ... program is the largest advertising competition in the world. With over ... arguably toughest advertising competition. The ADDY Awards represents the true spirit ...
... ... ... , ... , ...
... the rate of growth of the cancer tumour. The standard ... This is the conclusion of scientists at the University of ... The principal reason that patients die of cancer is the ... tumours known as metastases. These metastases are initially so small ...
Cached Medicine News:Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 2Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 3Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 4Health News:Want to Live a Healthier Lifestyle? Now There's an App for That, Too! 5Health News:Violent crime 'race gap' narrows, but persists in US 2Health News:Violent crime 'race gap' narrows, but persists in US 3Health News:ADD Insights, LLC and The New England ADHD Treatment Center Announce a Joint Seminar Series: Mastering One's ADHD 2Health News:ADD Insights, LLC and The New England ADHD Treatment Center Announce a Joint Seminar Series: Mastering One's ADHD 3Health News:Lunar Cow Design Wins 4 Addy Awards From The American Advertising Federation 2Health News:Lunar Cow Design Wins 4 Addy Awards From The American Advertising Federation 3Health News:Special Session Highlights Late-Breaking Abstracts 2Health News:Special Session Highlights Late-Breaking Abstracts 3Health News:Special Session Highlights Late-Breaking Abstracts 4Health News:Special Session Highlights Late-Breaking Abstracts 5
... The wrap frame is constructed of ... while minimizing potential breakage. The molded ... a full saddle bridge to distribute weight ... peripheral vision with leaded glass side shields. ...
... Constructed of optical steel base ... overlay. Comes with custom fitted ... create a seal to the ... from oblique angle exposure. Includes ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... frames are designed with the safety and comfort ... Schott RS-520 (also called SF-6) leaded glass, the ... meet standards, as set for optical clarity, visible ... our eyewear is protecting your eyes, it also ...
Medicine Products: